Tapewire

Nasdaq · USD

CAI

Caris Life Sciences, Inc.

Export transactions ↓
Tapewire entity
3706
SEC CIK
0002019410
Parsed reports
67

Last 12 months

Inside the activity.

4 purchase rows · 7 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202520
Dec 202502
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202620
Jun 202600
Jul 202600
Aug 202600
Sep 202605
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
March 25, 2025 Filed Jun 23, 2025 18:33 UTC
HALBERT DAVID DDirector · See Remarks · 10% owner
Caris Halbert, L.P.Director · 10% owner
GrantCommon Stock 360,750 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-061808 · tm2518641-4_4seq1.xml · nonDerivative · entry 1

HALBERT DAVID D · CIK 0001034380 · Director · See Remarks · 10% owner

Caris Halbert, L.P. · CIK 0002072109 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,023,250

F1 · shares: Represents an award of restricted stock units that vest in accordance with the applicable grant agreement. These restricted stock units were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.

Read SEC document
March 03, 2025 Filed Jun 23, 2025 22:41 UTC GrantStock Option · Derivative 750,000 $0.00 Strike: $18.60 $0.00
Disclosure

SEC source: 0001104659-25-061815 · tm2518641-9_4seq1.xml · derivative · entry 5

Spetzler David Baxley · CIK 0002071953 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common Stock · 750,000 shares

Expires 2035-03-03

F4 · derivative.exercise_date: The stock option vested 60% at grant and will vest 20% on August 11, 2025 and 20% on August 11, 2026. These securities were previously reported on the Reporting Person's Form 3.

Read SEC document
March 03, 2025 Filed Jun 23, 2025 22:41 UTC Disposition to issuerCommon Stock 700,509 $18.60 $13,029,467.40
Disclosure

SEC source: 0001104659-25-061815 · tm2518641-9_4seq1.xml · nonDerivative · entry 1

Spetzler David Baxley · CIK 0002071953 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,240

F1 · price: Represents shares of Common Stock surrendered to the Issuer as repayment for an outstanding promissory note.

F2 · balance_after: Includes 151,750 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreements, which securities were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.

Read SEC document
March 03, 2025 Filed Jun 23, 2025 22:34 UTC GrantStock Option · Derivative 255,000 $0.00 Strike: $18.60 $0.00
Disclosure

SEC source: 0001104659-25-061810 · tm2518641-5_4seq1.xml · derivative · entry 5

Denton John Russel · CIK 0002071923 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,000

Underlying: Common Stock · 255,000 shares

Expires 2035-03-03

F4 · derivative.exercise_date: The stock option vested 60% at grant and will vest 20% on September 1, 2025 and 20% on September 1, 2026. These securities were previously reported on the Reporting Person's Form 3.

Read SEC document
March 03, 2025 Filed Jun 23, 2025 22:34 UTC Disposition to issuerCommon Stock 238,230 $18.60 $4,431,078.00
Disclosure

SEC source: 0001104659-25-061810 · tm2518641-5_4seq1.xml · nonDerivative · entry 1

Denton John Russel · CIK 0002071923 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,770

F1 · price: Represents shares of Common Stock surrendered to the Issuer as repayment for an outstanding promissory note.

F2 · balance_after: These securities were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.

Read SEC document
February 27, 2025 Filed Jun 23, 2025 22:38 UTC
HALBERT JONDirector
GrantCommon Stock 16,129 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-061813 · tm2518641-7_4seq1.xml · nonDerivative · entry 1

HALBERT JON · CIK 0001189394 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,129

F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. These restricted stock units were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.

Read SEC document
February 27, 2025 Filed Jun 23, 2025 22:31 UTC GrantStock Option · Derivative 2,500 $0.00 Strike: $18.60 $0.00
Disclosure

SEC source: 0001104659-25-061804 · tm2518641-2_4seq1.xml · derivative · entry 4

CASTLEMAN PETER M · CIK 0001239594 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires 2035-02-27

F4 · derivative.exercise_date: The stock option is fully vested and exercisable. These securities were previously reported on the Reporting Person's Form 3.

Read SEC document
February 27, 2025 Filed Jun 23, 2025 22:31 UTC GrantCommon Stock 16,129 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-061804 · tm2518641-2_4seq1.xml · nonDerivative · entry 1

CASTLEMAN PETER M · CIK 0001239594 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,129

F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. These restricted stock units were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.